Samsung Biologics, 117,449 Shares Net Sold by Individuals in Last 5 Days... Stock Price 806,000 KRW (-0.74%)

As of 10:31 AM on the 19th, Samsung Biologics is trading at 806,000 KRW, down 0.74% from the previous day. The trading volume is 118,929 shares, which is about 29.74% of the previous day's volume. Samsung Biologics is known as the bio business holding company of the Samsung Group.

On November 16, Jiha Kim, a researcher at Meritz Securities, announced a target price of 900,000 KRW for Samsung Biologics, stating, "The CMO shortage phenomenon continues, allowing additional orders using buffer CAPA. From 4Q20, the company has entered a performance growth phase due to increased utilization of Plant 3. The utilization rate of Plant 3 at the end of 2021 is estimated to be 51%, up 20 percentage points compared to 2020, and batch prices are also expected to rise due to the shortage situation. It is presented as the top pick within the biosimilar sector. Performance improvement is expected with the increased utilization of Plant 3 in 2021. There is also anticipation of increased contract amounts from commercial production if Vir/GSK succeeds in developing a COVID-19 treatment."

Over the past five days, individual investors have net sold 117,449 shares of Samsung Biologics, while foreign investors and institutions have net bought 78,237 shares and 36,229 shares, respectively.

※ Source: AI Investment Assistant AI Rassiro

※ This article was generated in real-time by an automatic article generation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.

This content was produced with the assistance of AI translation services.